SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Supernus reported Q3 2026 total revenues of $226.8M (18% YoY growth), with four core products generating $192.2M (29% YoY growth). Key drivers: Qelbree $90.8M (+12%), GOCOVRI $42.6M (+4%), ONAPGO $17.1M (+151%), and ZURZUVAE collaboration revenue $41.7M (+107%). The company received orphan-drug exclusive approval for ONAPGO and submitted sNDA for second supplier. The all-stock merger with Indivior Pharmaceuticals is expected to close November 2, 2026, with anticipated $125M annual cost synergies; both boards approved on October 15, 2026.
Why this rating
Strong organic revenue growth (+18-29%) and profitable Q3 ($21M operating earnings) are positive. However, the pending merger is the dominant event—it's transformational for a $1.7B company, creating scale and diversification, but introduces execution risk, integration costs, and near-term uncertainty. Relative to company size, the merger and guidance raise (raising $875-900M from $860-890M) matter materially, though financials alone do not shift trajectory until post-close.
Price action (we called it positive)
before filing · preread $41.84 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.